search
Back to results

Oral Verapamil in Acute Paroxysmal Supra Ventricular Tachycardia(PSVT) Recurrence Control

Primary Purpose

Paroxysmal Supraventricular Tachycardia

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Verapamil
Sponsored by
Tehran University of Medical Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Paroxysmal Supraventricular Tachycardia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age>18 years old
  • PSVT on emergency department presentation

Exclusion Criteria:

  • Instability in hemodynamic status
  • Allergy to Verapamil

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Verapamil

    Arm Description

    40 mg Verapamil Per Oral

    Outcomes

    Primary Outcome Measures

    Recurrence Control

    Secondary Outcome Measures

    Full Information

    First Posted
    July 30, 2012
    Last Updated
    November 12, 2012
    Sponsor
    Tehran University of Medical Sciences
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01655316
    Brief Title
    Oral Verapamil in Acute Paroxysmal Supra Ventricular Tachycardia(PSVT) Recurrence Control
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    November 2012
    Overall Recruitment Status
    Completed
    Study Start Date
    October 2010 (undefined)
    Primary Completion Date
    August 2011 (Actual)
    Study Completion Date
    August 2011 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Tehran University of Medical Sciences

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    PSVT is a common rhythm disorder in emergency department which can be recurrent in some cases. Intravenous Adenosine is the drug of choice in PSVT control in acute settings but is a very short acting agent. Providing a complementary medication to decrease the rate of recurrence of PSVT after its initial control will be promising. This study evaluates the role of the oral Verapamil in recurrence control of PSVT in emergency situations.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Paroxysmal Supraventricular Tachycardia

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Single Group Assignment
    Masking
    Participant
    Allocation
    N/A
    Enrollment
    90 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Verapamil
    Arm Type
    Experimental
    Arm Description
    40 mg Verapamil Per Oral
    Intervention Type
    Drug
    Intervention Name(s)
    Verapamil
    Primary Outcome Measure Information:
    Title
    Recurrence Control
    Time Frame
    2 hours

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Age>18 years old PSVT on emergency department presentation Exclusion Criteria: Instability in hemodynamic status Allergy to Verapamil

    12. IPD Sharing Statement

    Learn more about this trial

    Oral Verapamil in Acute Paroxysmal Supra Ventricular Tachycardia(PSVT) Recurrence Control

    We'll reach out to this number within 24 hrs